The purpose of the study is to determine whether a three‑month course of MPD can improve thinking, attention, and overall quality of life compared with a control pill, which is a placebo. The trial is designed so that neither the participants nor the investigators know who receives the active drug or the control pill, ensuring an unbiased comparison.

Participants will take study tablets daily for three months and attend regular visits where simple brain‑activity recordings (explained as tests that measure the brain’s electrical signals) and mental‑function assessments (explained as tests that evaluate memory, problem‑solving, and attention) are performed, along with questionnaires about daily living and wellbeing.

The purpose of this study is to investigate the effect of Cannabidiol on sleep efficiency following late evening exercise. Sleep efficiency is a measure that compares the time spent actually sleeping to the total time spent in bed. The study will examine whether taking Cannabidiol affects how well people sleep after exercising late in the evening. The study will also look at other aspects of sleep quality, how people feel about their sleep, and measure certain hormones and chemical substances in the blood and urine that are related to sleep and stress.

During the study, participants will take part in different sessions where they will receive either Cannabidiol or Softisan 378. The maximum daily amount of Cannabidiol that can be given is 400 milligrams, while the maximum daily amount of Softisan 378 is 1200 milligrams. The study will measure changes in sleep patterns between the different sessions and collect blood and urine samples to analyze various substances that affect sleep. Participants will be healthy adults between 18 and 40 years old who exercise regularly and have good sleep quality to begin with.

The purpose of this study is to find out how these hormone medications affect blood sugar control in women with diabetes who are experiencing menopause symptoms. The study will look at whether using estradiol patches combined with progesterone capsules helps to keep blood sugar levels within a healthy range. During the study, participants will have periods where they receive the hormone treatment and periods where they do not receive treatment. Blood sugar levels will be measured continuously using a monitoring device worn on the body for two weeks at different times during the study.

The study will also look at other health measures, including how well insulin works in the body, changes in blood pressure, cholesterol levels, liver fat content, muscle strength, and various symptoms related to menopause and diabetes. Participants will complete questionnaires about their symptoms, sleep quality, mood, and overall quality of life. Some participants will undergo additional tests such as an MRI scan to measure liver fat and specialized tests to measure how the body responds to insulin. The entire treatment period will last up to 60 months, during which participants will be monitored to see how the hormone treatment affects their diabetes control and overall health.

The purpose of the study is to find out if 6QC-ICG is safe and well-tolerated when applied to tissue, and whether it can help doctors see any remaining cancer cells during surgery. The study has two parts. Part A involves healthy volunteers who will have the substance applied to a small wound on their skin to check for any unwanted effects. Part B involves patients who have been diagnosed with a specific type of breast cancer and are scheduled to have surgery. During their operation, the substance will be applied to the area where the tumor was removed to see if it lights up any remaining cancer cells that might need to be taken out.

Throughout the study, researchers will carefully monitor participants for any side effects or problems. They will check vital signs like blood pressure and heart rate, take blood and urine samples for laboratory tests, and perform heart rhythm tests using an ECG. For the patients having surgery, doctors will take pictures using special cameras that can see the fluorescent signal from the imaging agent, and they will compare these images with laboratory results from tissue samples to see how well the substance works at identifying cancer cells.

During the study, participants will receive either oxytocin nasal spray or a placebo nasal spray containing salt water. The treatment will be given through the nose for up to 5 days. Throughout the study period, participants will complete various questionnaires about their stress levels, emotional state, sleep quality, and thinking abilities. They will also perform some computer-based tasks to assess their cognitive function.

The study aims to understand if using oxytocin nasal spray can help reduce psychological distress that many people experience after breast cancer treatment. The research will measure changes in stress levels, anxiety, depression, and overall quality of life to determine if this treatment approach could be beneficial for breast cancer survivors.

The purpose of this research is to understand how these two different anesthesia medications affect kidney blood flow in children who need to undergo Magnetic Resonance Imaging (MRI). During the study, children will receive either propofol or sevoflurane while having their MRI scan. Special imaging techniques will be used to look at how blood flows through the kidneys during anesthesia.

The study involves children between 1 month and 14 years of age who already need to have an MRI scan with anesthesia as part of their regular medical care. During the procedure, researchers will measure kidney blood flow and oxygen levels using special MRI techniques. They will also take a blood sample to measure certain kidney-related substances in the blood.

The study involves four different groups of participants, with each group receiving one of the treatments mentioned above. The medications are administered over an 8-week period. Triptorelin is given as an injection into the muscle, while both estradiol and testosterone are applied to the skin as gels. Some participants will receive placebo treatment instead of active medication.

During the study, researchers will monitor changes in bone health markers and other body functions. The study will also track changes in various aspects of participants’ health, including hormone levels, quality of life, sleep patterns, and other health indicators. Regular check-ups and blood tests will be performed to ensure participant safety throughout the study period.

The medications being studied include ZIMHI™ (naloxone hydrochloride injection) for intramuscular use, NARCAN® (naloxone hydrochloride) nasal spray, and Naloxone 400 micrograms/ml solution for injection/infusion. Additionally, Fentanyl, a powerful opioid, is also part of the study to understand its interaction with naloxone. The study will involve administering these medications to participants and observing their effects on breathing and other bodily functions.

Participants will receive multiple doses of either the intramuscular or intranasal form of naloxone, and researchers will monitor how quickly and effectively each form works to reverse the effects of opioids. The study will also measure various factors such as the concentration of naloxone and fentanyl in the blood, as well as changes in pupil size and muscle tone. This research aims to provide valuable insights into the best ways to treat opioid overdoses and improve patient outcomes.

The trial will use two medications: zolpidem, which is a film-coated tablet, and mannitol, which is a capsule. Participants will take these medications orally, either by mouth or through a tube if necessary. The study will observe how these medications affect the participants over a short period, with a focus on understanding the unique reactions some people have to zolpidem.

Throughout the study, researchers will monitor various aspects such as consciousness levels, alertness, and cognitive performance. They will also use techniques like high-density electroencephalography (hdEEG) to study brain activity. The findings from this study could lead to better understanding and treatment options for those who experience paradoxical responses to zolpidem.

The purpose of the study is to see how effective these medications are in reducing body temperature without causing shivering. Participants will be exposed to a cold environment in a controlled setting, and their body temperature will be monitored throughout the process. The study will compare the effects of the active medications against the placebo to determine their effectiveness in managing hypothermia.

During the study, participants will receive the medications through different methods, such as intravenous (directly into the vein) or oral (by mouth) administration. The study will last for a short period, and participants will be closely monitored for any changes in their body temperature and overall health. The goal is to gather information on how these treatments can help manage hypothermia safely and effectively.

Participants in the study will receive Esketamine and Remifentanil through an injection or infusion, which means the medication is delivered directly into the bloodstream. The study will also use a solution called normal saline, which is a simple saltwater solution, as part of the process. Another medication, Naloxone Hydrochloride, may be used to help understand the effects of the other drugs. The purpose of the study is to observe how these medications interact with the body’s natural response to low oxygen levels.

The study will take place over a short period, with participants experiencing controlled low oxygen levels for specific durations. The researchers will monitor the participants’ breathing and any side effects, such as changes in mood or perception, which are known as psychomimetic side effects. The study will also measure the levels of Esketamine in the blood to better understand its effects. This research aims to provide insights into how these medications can be used safely and effectively in medical settings.

The purpose of the study is to understand how these medications can help reverse the breathing difficulties that opioids can cause. Participants will receive either the medication or a placebo, and their breathing will be monitored to see how well the medications work. The study will involve both people who are new to opioids and those who have been using them for a long time.

Throughout the study, participants will receive the medications through injections or nasal sprays, and their breathing will be closely observed. The study aims to gather information on how quickly and effectively these medications can reverse the effects of opioids on breathing. This research is important for improving treatments for people who experience breathing problems due to opioid use.

The purpose of the study is to compare the porosity, or how easily fluid passes through, of the superficial lymphatic vessels in women with lipedema versus those in healthy individuals. This will help determine if the imaging technique, known as Near Infra-Red Fluorescence Imaging (NIRFI), can be a useful tool for diagnosing lipedema. The study involves injecting the indocyanine green just under the skin and then using the imaging technique to observe how the lymphatic vessels behave.

Participants in the study will undergo this imaging process, and researchers will observe the fluorescence in the area around the lymphatic vessels. They will also measure how quickly the contrast moves through the vessels and the pressure needed to block the flow in these vessels. The study is designed to provide insights into the differences in lymphatic vessel function between those with lipedema and those without, potentially leading to better diagnostic methods for this condition.

Participants in the study will be randomly assigned to receive either the estetrol monohydrate tablet or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. The main focus will be on measuring changes in hair growth, specifically looking at the number and width of non-vellus hair, which is the thicker type of hair, at the end of the study period. Additionally, the study will evaluate the safety of the treatment and its effects on the endometrium, which is the lining of the uterus, as well as monitor any vaginal bleeding in participants who have not had a hysterectomy.

The study will last for approximately six months, during which participants will be asked to maintain their usual hair care routines and hairstyles. Regular assessments will be conducted to monitor hair growth and overall health. The study aims to provide valuable insights into the potential benefits and safety of estetrol monohydrate for improving hair growth in postmenopausal women experiencing hair loss.

Participants in the study will be randomly assigned to receive either rifaximin or a placebo, which is a tablet that looks like the medication but does not contain the active ingredient. The study will observe how the medication affects various responses, such as stress levels measured by saliva tests, skin reactions, and heart rate. Additionally, the study will look at changes in gut bacteria and other health markers.

The trial is designed to be “triple-blind,” meaning that neither the participants, the researchers, nor the people analyzing the results will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased. The study will take place over a period of time, with participants taking the medication or placebo and undergoing various tests to measure their responses to stress and fear.

The purpose of the study is to understand how growth hormone affects the liver’s ability to process fats and energy. Participants will receive either the medication or a placebo, and the study will observe changes in the body’s energy use, liver fat content, and the production of certain types of fat in the liver. The study will also look at how these changes affect overall body composition and energy expenditure.

Participants will be involved in the study for a short period, during which they will receive injections and undergo various assessments to monitor the effects of the treatment. The study aims to provide insights into how growth hormone influences liver function and fat metabolism, which could have implications for treating conditions related to growth hormone levels.

Participants in the study will receive these medications through an intravenous infusion, which means the drugs are delivered directly into the bloodstream through a vein. The study will also use a placebo for comparison. The main goal is to see if acetylcysteine can help reverse the breathing problems caused by fentanyl. Additionally, the study will monitor various aspects of breathing, such as how much air is inhaled and exhaled in a minute, the levels of carbon dioxide in the breath, and other related measures.

The trial will take place over a short period, with participants receiving the treatments and being closely monitored for any changes in their breathing patterns. The study aims to provide valuable insights into how these medications interact and whether acetylcysteine can be an effective treatment for breathing issues caused by opioid medications like fentanyl.

The purpose of the study is to understand how different doses of promethazine and varying gravity levels impact the performance of tasks that require the use of both hands. Participants will be exposed to different gravity levels and will perform tasks that test their coordination. The study will observe how well participants can perform these tasks under the influence of the medication and during rapid changes in gravity.

Participants in the study will include healthy volunteers who will be given either promethazine or a placebo. The study will monitor their performance on coordination tasks to see if the medication or changes in gravity affect their ability to perform these tasks. The findings from this study could provide valuable insights into how medications like promethazine and altered gravity conditions influence human motor skills.

The purpose of the study is to evaluate whether using Esmolol is as effective as using Sufentanil for improving patient comfort after surgery. Participants will be randomly assigned to receive either Esmolol or Sufentanil during their anesthesia. After the surgery, the quality of recovery will be assessed using a questionnaire the day after the procedure. The study will also monitor other factors such as pain levels, any sore throat, changes in blood pressure, heart rate, and the need for additional medications during the operation.

The trial is designed to ensure that the recovery process is as comfortable as possible for patients undergoing this type of surgery. By comparing these two medications, the study aims to find the best approach to enhance recovery and overall patient experience after a laparoscopic cholecystectomy.

Two different solutions for infusion will be used in this study. One is called Suero Fisiológico Vitulia 0.9% solution for infusion, which contains sodium chloride, a common salt used to help maintain fluid balance in the body. The other is Lactato Ringer Braun solution for infusion, which contains a mix of potassium chloride, sodium chloride, calcium chloride dihydrate, and sodium lactate. These substances are used to help restore the balance of electrolytes, which are minerals in the body that carry an electric charge and are essential for many bodily functions.

The purpose of the study is to determine if this new treatment approach can improve outcomes for patients with septic shock, such as reducing the risk of death, shortening the time patients need vital support, and decreasing the length of hospital stay, all within 28 days. Participants in the study will receive either the new treatment approach or the usual care, and their progress will be monitored over this period. The study will help to understand if this new method can provide better results compared to the standard treatment currently used for septic shock.

The purpose of the study is to monitor the safety of relacorilant over an extended period. Participants in the study will continue to receive relacorilant and will be regularly assessed for any side effects or changes in their health. This includes checking for any new or worsening symptoms, as well as conducting routine health checks such as blood tests, physical exams, and heart monitoring using electrocardiograms (ECGs). For those with a specific type of Cushing Syndrome caused by a pituitary tumor, magnetic resonance imaging (MRI) scans will be used to observe any changes in the tumor.

Throughout the study, participants will have regular visits to the study site to ensure their well-being and to gather important information about the effects of relacorilant. The study aims to provide valuable insights into the long-term use of relacorilant for managing the symptoms of Endogenous Cushing Syndrome, helping to improve treatment options for those affected by this condition.

Participants in the study will be randomly assigned to receive either the Qutenza patch or a low-dose capsaicin patch. The study will last for several weeks, during which participants will have their pain levels monitored regularly. The main goal is to observe changes in pain intensity from the start of the study to the end of the 12-week period. The study will also look at any side effects that may occur during the treatment.

The trial is designed to help understand how well Qutenza works in reducing pain and to ensure it is safe for use. Participants will be closely monitored throughout the study to gather information on how the treatment affects their pain and overall health. This research is important for developing better treatments for people who suffer from post-surgical neuropathic pain.

The purpose of this study is to determine if adding sildenafil to the current treatment regimen of these patients can enhance their physical performance. Sildenafil is a medication that is often used to treat conditions related to blood flow. In this study, participants will receive either sildenafil or a placebo for a period of 24 weeks. Throughout the study, various tests will be conducted to assess improvements in exercise capacity, heart function, and overall quality of life.

Participants will undergo tests such as the ergospirometry test, which measures oxygen uptake during exercise, and the 6-minute walk test, which evaluates the distance they can walk in six minutes. Other assessments will include echocardiography to examine heart function and questionnaires to gauge quality of life. The study aims to provide insights into whether sildenafil can be a beneficial addition to the treatment of patients with a functionally single ventricle after the Fontan operation.

Participants in the study will receive Levosimendan as a solution for infusion, which means it will be administered directly into the bloodstream through a drip. The study will also involve a comparison with a placebo to evaluate the effectiveness of the treatment. The main goal is to see if Levosimendan can reduce the risk of a complication called cerebral arterial vasospasm, which is a narrowing of the blood vessels in the brain that can occur after the initial bleeding.

The study will follow participants for a period of time to monitor the occurrence of vasospasms and other outcomes such as the rate of death, the impact on heart function, and recovery scores six months after treatment. This research is important to understand if Levosimendan can improve outcomes for patients with this serious condition.

The main goal of the study is to observe and compare how these medications affect the feelings and emotions of patients before they undergo general anesthesia for surgery. Participants will receive one of the three opioids in specific doses through an injection. The study will monitor how the patients feel after receiving the medication, focusing on their emotional state and any sensations they experience. This will help researchers understand the different effects these opioids have on patients’ feelings and emotions.

Throughout the study, participants will be asked to rate their feelings using a simple scale. This includes how good, anxious, or relaxed they feel, as well as any pain they might experience. The study will also look at other effects, such as heart rate changes, to gather more information about how these medications work. By comparing the results from different groups, the study aims to provide insights into the emotional effects of these commonly used opioids in a surgical setting.

The purpose of the study is to evaluate the safety of OP-1250 and to see how well it works compared to the standard treatments. Participants in the study will receive either OP-1250 or one of the standard treatments. OP-1250 is taken as a tablet by mouth, while some of the standard treatments are given as injections. The study will last for a period of up to 42 days, during which the effects of the treatments will be monitored.

Throughout the study, doctors will closely observe participants to ensure their safety and to gather information on how the treatments affect the cancer. This includes checking for any side effects and measuring how the cancer responds to the treatment. The information collected will help determine if OP-1250 could be a better option for treating this type of breast cancer in the future.

The purpose of the study is to see if these treatments can stimulate the brain’s cleaning system, known as the glymphatic system, to remove amyloid deposits more effectively. Participants in the study will receive either nVNS, sodium oxybate, or both. Some participants may receive a placebo. The study will last for a period of up to 12 months, during which the effects of the treatments will be monitored and compared to the participants’ condition before starting the treatment.

Throughout the study, participants will have regular check-ups to assess the levels of amyloid in their cerebrospinal fluid, which is the fluid surrounding the brain and spinal cord. This will involve a procedure called a lumbar puncture, where a small amount of fluid is taken from the lower back. The study aims to determine if the treatments can reduce amyloid levels and improve the condition of patients with cerebral amyloid angiopathy.

The purpose of this study is to compare how well the combination of Capivasertib and Abiraterone works against the combination of a placebo and Abiraterone in patients with this specific type of prostate cancer. The study will monitor how long patients live without their cancer getting worse, which is known as radiographic progression-free survival. Participants will be randomly assigned to receive either the Capivasertib and Abiraterone combination or the placebo and Abiraterone combination. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving which treatment until the study is completed.

Throughout the study, participants will take the medication orally and will have regular check-ups to monitor their health and the progression of their cancer. The study aims to provide valuable information on the potential benefits of adding Capivasertib to the treatment regimen for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial is expected to continue until 2027, with recruitment starting in 2024.

Participants in the study will be randomly assigned to receive either the SPIOMET treatment or a placebo. The study will last for a period of 12 months, during which the participants will take the medication in tablet form. Throughout the study, various health parameters will be monitored, including bone development, weight, height, and hormone levels. The study aims to observe any changes in these parameters to assess the effectiveness of the treatment.

In addition to monitoring physical changes, the study will also evaluate the safety of the treatment by checking blood tests and other health markers. The goal is to ensure that the treatment is not only effective but also safe for the participants. The study will provide valuable insights into managing conditions related to early puberty and PCOS in young girls, potentially leading to better treatment options in the future.

Table of contents

• Trial overview
• Who can participate
• What is being measured
• Study design and phase
• What the trial is trying to learn

Trial overview

The available study is an interventional trial, which means the research team gives the study treatment and then checks what happens.^[1] It is authorised and planned for 22 people.^[1]

The trial title says it studies the effect of 6QC-ICG on the skin of healthy volunteers and in patients with breast cancer during surgeries.^[1] The brief summary explains that Part A looks at safety and tolerability on wounded skin in healthy volunteers, while Part B looks at safety and tolerability during surgery for breast conserving surgery in patients with breast cancer.^[1]

Who can participate

One group in the study is healthy volunteers, who are people without the cancer being studied.^[1] In this part, the treatment is applied to wounded skin to see how the skin responds.^[1]

The other group is patients with breast cancer who are having breast conserving surgery.^[1] This means the study is not only about healthy skin, but also about use during an operation for cancer care.^[1]

Study design and phase

This is a Phase 1/2 study.^[1] Phase 1 studies mainly look at safety and tolerability, while Phase 2 studies begin to explore whether the approach may help with the medical problem being studied.

The interventions listed are 6QC-ICG given as a topical application on wound and a placebo for 6QC-ICG.^[1] A placebo is a comparison treatment that does not contain the active study product, and it helps researchers judge the true effect of the study treatment.

What is being measured

The main outcomes focus on local tolerability and systemic safety.^[1] Local tolerability means how the treated skin area reacts, and systemic safety means whether the treatment causes effects in the rest of the body.

The study measures pain and itching using numeric rating scales, which are simple scales where people rate how strong a symptom feels.^[1] It also tracks local and systemic treatment-emergent serious and non-serious adverse events, which are medical problems that appear during the study.^[1]

Researchers also check vital signs, including pulse rate and blood pressure, to watch basic body functions during the study.^[1] In addition, the trial includes clinical laboratory tests such as hematology, blood chemistry, and urinalysis, plus ECG measurements like heart rate, PR, QRS, QT, and QTcF.^[1]

The study also records concomitant medication, which means any other medicines the participant is taking during the trial.^[1]

What the trial is trying to learn

Part A is designed to learn whether a single dose of topically applied 6QC-ICG is safe and well tolerated on wounded skin in healthy volunteers.^[1]

Part B is designed to learn whether the same single-dose topical use is safe and well tolerated for intraoperative visualization of residual breast cancer during breast conserving surgery.^[1] In simple words, the study is asking whether 6QC-ICG can help surgeons see remaining cancer during the operation while also staying safe for the patient.^[1]

Table of contents

• Trial overview
• Who is being studied
• What is being measured
• Study design and phase
• Why this research matters

Trial overview

This source describes one interventional study, which means the researchers give a study treatment and then measure what happens.^[1] The trial title is “Mechanisms of Action of Paradoxical Responses to Zolpidem: A Multimodal Study.”^[1] The study status is Suspended, so it is not currently moving ahead as planned.^[1]

Who is being studied

The trial includes three groups: patients with disorders of consciousness (DoC), patients with acquired partial or total vision impairment, and neurotypical volunteers, which means people from the general population used for comparison.^[1] The brief summary says the researchers are interested in people who may show a paradoxical response to ZOLPIDEM TARTRATE, meaning an unexpected response rather than the usual one.^[1]

In the DoC group, the researchers are looking at whether some participants may recover consciousness after the study intervention.^[1] In the vision-impaired group, they are looking at whether some participants may have a temporary return of vision.^[1] In neurotypical volunteers, the summary notes possible changes such as trouble falling asleep, higher concentration, and increased agitation in paradoxical responders.^[1]

What is being measured

The main outcomes are different for each group, but they all help researchers understand response patterns.^[1] For patients with DoC, the study measures consciousness level using the Coma Recovery Scale-Revised (CRS-R), brain complexity using high density electroencephalography (hdEEG), and patient experiences through free recall or interview if functional communication returns.^[1]

For neurotypical volunteers, the study measures alertness or sleepiness with the Karolinska Sleepiness Scale (KSS), cognitive performance with standardised neuropsychological tests, brain complexity with hdEEG, and any reported experiences through free recall or interview.^[1] For patients with acquired vision impairment, the same alertness, cognitive, brain, and experience measures are used, plus visual function testing by a neuro-ophthalmologist, who is an eye specialist focused on the nervous system and vision.^[1]

Study design and phase

The study is listed as Phase 2.^[1] Phase 2 studies usually look more closely at whether a treatment has an effect in the target groups and continue to collect information about outcomes.^[1] The planned enrollment is 180 participants.^[1]

The intervention list includes Zolpidem Viatris 10 mg tablets and mannitol, with administration by oral, nasogastric tube, or percutaneous endoscopic gastrostomy tube use as stated in the source.^[1] The source does not provide more detail on dosing schedules beyond this listing.^[1]

Why this research matters

The brief summary says the study aims to better understand the mechanisms behind paradoxical responders versus non-paradoxical responders to ZOLPIDEM TARTRATE.^[1] This matters because the same treatment may lead to very different results across people, and the researchers want to learn which brain, behavior, or vision changes may help explain those differences.^[1] The summary also says the findings could support improved personalised patient care.^[1]

Table of Contents

• Trial overview
• Breast cancer studies
• Prostate cancer studies
• Fertility and reproductive studies
• Other studies
• Main endpoints being measured
• Who can participate

Trial overview

The trial data show that Triptorelin is being studied in several different settings, mainly breast cancer, prostate cancer, and fertility treatment.^[1][2] Most studies are Phase 2 or Phase 3 trials, which means they are testing how well the treatment works in larger patient groups and, in some studies, comparing it with other options.^[1][2] Several studies are authorised, some are completed, and one study in the source data is withdrawn.^[1]

Breast cancer studies

Many Triptorelin trials focus on women with ER-positive/HER2-negative or HR-positive/HER2-negative early breast cancer, including both premenopausal and high-risk groups.^[2][3] In these studies, Triptorelin is used with other endocrine treatments, and the trials aim to see whether the treatment plan lowers cancer growth, delays recurrence, or improves invasive breast cancer-free survival.^[2][3]

One Phase 2 study in premenopausal women with operable breast cancer compared giredestrant plus Triptorelin with anastrozole plus Triptorelin, and also looked at giredestrant without Triptorelin.^[2] Its main endpoint was the change in Ki-67, a marker that shows how fast tumor cells are growing, measured between a biopsy before treatment and a biopsy after treatment.^[2]

Large Phase 3 trials also study Triptorelin in early breast cancer, including studies of adjuvant endocrine-based therapy and personalized treatment strategies in young women.^[3][4] These trials measure outcomes such as IBCFS, which is the time until an invasive breast cancer event, a new cancer in the other breast, or death.^[3][4]

Another completed Phase 2 study in metastatic breast cancer compared alpelisib-fulvestrant with ribociclib-fulvestrant in patients with persistent PIK3CA mutations after early treatment with a CDK4/6 inhibitor and fulvestrant.^[5] Triptorelin was one of the hormone treatment options listed in that study, and the main endpoint was progression-free survival.^[5]

Prostate cancer studies

Triptorelin is also studied often in prostate cancer, including localised, locally advanced, recurrent, oligometastatic, and metastatic disease.^[6][7] These studies usually compare different hormone treatment strategies, sometimes together with radiotherapy, and they look at whether the cancer stays controlled for longer or whether the risk of metastasis is reduced.^[6][7]

In a Phase 3 study of very high-risk localised or locally advanced prostate cancer, Triptorelin was one of several GnRH agonists compared with other hormone options alongside radiotherapy.^[6] The main endpoint was the proportion of patients reaching a PSA nadir below 0.1 ng/mL within 6 months after radiotherapy, which means the lowest PSA level achieved after treatment.^[6]

Another Phase 3 study looked at patients with oligorecurrent hormone-sensitive prostate cancer and tested whether adding short-term hormone therapy, including Triptorelin, to metastasis-directed therapy could delay poly-metastatic progression.^[7] That study measured poly-metastatic free survival, which is the time until the disease spreads to more than five new lesions on imaging or until treatment changes because of progression.^[7]

Other prostate cancer trials included Triptorelin in studies of salvage radiotherapy after surgery, darolutamide with or without radiation, and treatment approaches for metastatic castration-sensitive or castration-resistant disease.^[8][9] These studies measure outcomes such as metastasis-free survival, radiographic progression-free survival, biochemical disease-free survival, and quality of life.^[8][9]

Fertility and reproductive studies

Several Triptorelin trials are in fertility care, especially ovarian stimulation, embryo development, and fertility preservation.^[10][11] These studies involve women undergoing IVF, ICSI, oocyte donation, or planned fertility preservation, and they compare different stimulation or triggering approaches.^[10][11]

In ovarian stimulation studies, the main outcomes often focus on the number of MII oocytes, which are mature egg cells, or the number of good-quality blastocysts, which are early embryos with good development.^[10][11] For example, one Phase 3 trial compared intranasal nafarelin with subcutaneous Triptorelin to trigger final oocyte maturation, and another study compared different stimulation intensities in women undergoing PGT-A with a PPOS protocol.^[10][11]

Other fertility trials looked at live birth, clinical pregnancy, or the number of cumulus-oocyte complexes, which are egg cells surrounded by supporting cells collected after stimulation.^[12][13] One study also examined whether a GnRH agonist before frozen embryo transfer improves pregnancy rates in patients with endometriosis and/or adenomyosis.^[12]

There is also a Phase 3 study in women with low ovarian reserve and androgen receptor polymorphism that tested whether pretreatment with transdermal testosterone increases the number of cumulus-oocyte complexes after ovarian stimulation.^[13] This study was withdrawn in the source data, but it still shows the type of fertility questions being studied alongside Triptorelin.^[13]

Other studies

Triptorelin appears in a Phase 2 menopause study that compared a GnRH analog, transdermal estrogen, transdermal testosterone, and placebo over 8 weeks in postmenopausal women.^[14] The main outcome was the change in bone remodeling, measured through bone markers from baseline to week 8.^[14]

Another study looked at the use of Triptorelin in a Phase 1/II metastatic breast cancer trial combining [177Lu]Lu-NeoB with capecitabine, where Triptorelin was one of several hormone-related treatment options listed in the source data.^[15] The Phase I part focused on safety, dose-limiting toxicities, and tolerability, while the Phase II part looked at tumor response, clinical benefit, time to response, duration of response, progression-free survival, and overall survival.^[15]

Main endpoints being measured

The trial data show a wide range of endpoints, depending on the condition being studied.^[1] In cancer trials, common endpoints include survival without recurrence, progression-free survival, metastasis-free survival, PSA response, and changes in tumor markers such as Ki-67.^[2][6][8]

In fertility trials, the main endpoints often include the number of mature eggs, embryo quality, pregnancy rate, and live birth.^[10][11][12] In menopause research, the outcome is linked to bone marker changes, which help show how bone is being broken down or rebuilt.^[14]

Who can participate

Participation depends on the study and the disease being treated.^[1] The source data include premenopausal women with early or metastatic breast cancer, men with prostate cancer at different stages, women undergoing IVF or oocyte donation, postmenopausal women, and patients with endometriosis or adenomyosis.^{[2][6][10][12]}

Many studies have extra entry rules, such as hormone receptor status in breast cancer, the number of metastases in prostate cancer, or ovarian reserve in fertility trials.^[3][7][13] This means the trials are aimed at specific patient groups, not at everyone who uses Triptorelin in routine care.^[1]

Table of Contents

• What is Testosterone?
• Medical Uses of Testosterone
• Forms and Administration of Testosterone
• Effectiveness of Testosterone Therapy
• Potential Side Effects and Monitoring
• Ongoing Research and Future Directions

What is Testosterone?

Testosterone is a hormone that plays a crucial role in male health. It is primarily produced by the testes in men and is responsible for many masculine characteristics, such as muscle mass, body hair, and deep voice. In medical terms, testosterone is often referred to as an androgen, which means a male hormone^[1].

Medical Uses of Testosterone

Testosterone is primarily used to treat a condition called hypogonadism, which is when the body doesn’t produce enough testosterone on its own. This condition can cause various symptoms, including^[2][3]:

• Low energy levels
• Reduced muscle mass
• Decreased sexual function
• Changes in mood or cognitive function

In addition to hypogonadism, testosterone therapy is also being studied for its potential benefits in certain cases of prostate cancer. While this might seem counterintuitive, some research suggests that in specific situations, testosterone might help manage hormone-refractory prostate cancer, which is a type of prostate cancer that no longer responds to standard hormone therapy^[1].

Forms and Administration of Testosterone

Testosterone replacement therapy comes in several forms, each with its own advantages. Some of the common forms include^[4][1][5]:

• Testosterone pellets (Testopel®): These are small pellets implanted under the skin, usually in the hip area. They slowly release testosterone over several months.
• Transdermal patches (Androderm®): These are patches applied to the skin daily, delivering a steady dose of testosterone.
• Oral capsules: Some forms of testosterone can be taken by mouth, such as testosterone undecanoate (LPCN 1021).

The choice of form depends on various factors, including patient preference, lifestyle, and specific medical needs.

Effectiveness of Testosterone Therapy

The effectiveness of testosterone therapy is typically measured by monitoring testosterone levels in the blood and assessing symptom improvement. Studies have shown that testosterone replacement can effectively raise testosterone levels to the normal range in most patients with hypogonadism^[2][3].

For example, one study found that after 24 days of treatment with oral testosterone undecanoate, a significant proportion of patients achieved normal testosterone levels^[2]. Another study using testosterone pellets showed that testosterone levels could be maintained in the therapeutic range for 4-6 months after a single implantation^[4].

Potential Side Effects and Monitoring

While testosterone therapy can be beneficial, it’s important to be aware of potential side effects. Regular monitoring is crucial to ensure safe and effective treatment. Some key aspects that are typically monitored include^[4][5]:

• Testosterone levels: To ensure they remain within the normal range.
• Hematocrit levels: Testosterone can increase red blood cell production, which might lead to blood thickening in some cases.
• PSA (Prostate Specific Antigen) levels: To monitor prostate health, as testosterone might affect the prostate gland.
• Estradiol levels: Some testosterone can be converted to estrogen in the body, so estradiol (a form of estrogen) is also monitored.
• Blood pressure: Some studies are investigating the effects of testosterone on blood pressure.

Ongoing Research and Future Directions

Research on testosterone therapy is ongoing, with scientists exploring its potential benefits and risks in various conditions. Some areas of current research include^[6][5]:

• The use of new imaging techniques, such as PET scans with special tracers, to better understand how testosterone interacts with prostate cancer cells.
• The effects of testosterone therapy on cardiovascular health, including blood pressure.
• The potential benefits of testosterone on quality of life, sexual function, and muscle strength in men with low testosterone levels.

These ongoing studies aim to provide a more comprehensive understanding of testosterone’s role in health and disease, potentially leading to improved treatments in the future.

Table of Contents

• What is Spironolactone?
• Uses of Spironolactone
• How Spironolactone Works
• Dosage and Administration
• Potential Side Effects
• Ongoing Research

What is Spironolactone?

Spironolactone, also known by the brand name Aldactone, is a medication that belongs to a class of drugs called mineralocorticoid receptor antagonists (MRAs)^[1]. It’s been approved by the Food and Drug Administration (FDA) for various uses and has been a subject of extensive research for its potential benefits in treating different conditions^[2].

Uses of Spironolactone

Spironolactone is used to treat several medical conditions:

• Heart Failure: It’s commonly used in the treatment of heart failure, particularly in patients with reduced left ventricular ejection fraction (a measure of how well your heart is pumping)^[1].
• High Blood Pressure: Spironolactone is approved to treat high blood pressure (hypertension)^[2].
• Edema: It’s used to treat fluid retention (edema) in patients with certain liver conditions^[2].
• Hyperaldosteronism: This is a condition where the body produces too much of a hormone called aldosterone^[2].
• Androgen Excess in Women: It’s used off-label (meaning not officially approved by the FDA for this purpose, but still prescribed by doctors) to treat conditions related to excess male hormones in women, such as acne, excess hair growth, and polycystic ovary syndrome (PCOS)^[3].

How Spironolactone Works

Spironolactone works by blocking the effects of a hormone called aldosterone in your body. Aldosterone is responsible for regulating salt and water balance in your body. By blocking aldosterone, spironolactone can:

• Help your body get rid of excess fluid
• Lower blood pressure
• Reduce the workload on your heart
• Block the effects of male hormones (androgens) in women

This unique mechanism makes spironolactone useful in treating various conditions related to fluid retention, high blood pressure, and hormonal imbalances^[1][3].

Dosage and Administration

The dosage of spironolactone can vary depending on the condition being treated and the individual patient. Here are some general guidelines based on the research studies:

• For heart failure: Doses typically range from 25mg to 50mg daily^[1].
• For high blood pressure: Doses may range from 25mg to 100mg daily^[2].
• For androgen excess in women: Doses may range from 50mg to 200mg daily^[3].

Spironolactone is usually taken orally in tablet form. It’s important to take it exactly as prescribed by your doctor and not to adjust your dose without consulting them first^[4].

Potential Side Effects

Like all medications, spironolactone can cause side effects. Some potential side effects include:

• Increased potassium levels in the blood (hyperkalemia)
• Breast tenderness or enlargement in men
• Menstrual irregularities in women
• Dizziness or headache
• Nausea or stomach upset

It’s important to discuss any side effects you experience with your healthcare provider. They can help determine if the benefits of the medication outweigh the risks for your specific situation^[1][3].

Ongoing Research

Spironolactone is currently being studied for several potential new uses:

• Alcohol Use Disorder: Researchers are investigating whether spironolactone could help reduce alcohol consumption in people with alcohol use disorder^[2].
• Melasma: This is a skin condition causing dark patches on the face. A study is looking at whether spironolactone could help treat this condition^[5].
• Kidney Protection: Some studies are exploring whether spironolactone could help protect the kidneys from damage in certain situations, such as after heart surgery^[6].
• Ovulation in Young Women: Researchers are studying whether spironolactone could improve ovulation rates in young women with excess male hormones^[3].

These studies are still ongoing, and more research is needed before spironolactone can be recommended for these uses. Always consult with your healthcare provider about the most current and appropriate treatments for your specific condition.

Table of Contents

• What is Sufentanil?
• Medical Uses of Sufentanil
• Administration Methods
• Effectiveness of Sufentanil
• Potential Side Effects
• Comparisons with Other Medications
• Ongoing Research

What is Sufentanil?

Sufentanil is a powerful opioid medication used for pain relief in medical settings. It belongs to a class of drugs called opioid analgesics, which work by binding to specific receptors in the brain and nervous system to reduce pain sensations. Sufentanil is considered to be significantly more potent than many other opioids, including morphine^[1].

This medication is known by various names, including:

• Sufenta Forte^[1]
• Zalviso (a specific sublingual tablet system)^[2]
• DSUVIA (another brand name)^[3]

Medical Uses of Sufentanil

Sufentanil is primarily used in medical settings for managing moderate to severe pain. Some of its common applications include:

1. Post-operative pain management: It’s often used to control pain after surgeries, particularly in procedures like total hip arthroplasty (THA) and total knee arthroplasty (TKA)^[3].
2. Anesthesia: Sufentanil can be part of the anesthesia protocol during surgeries, including cardiac procedures^[4].
3. Acute pain relief: It’s used in emergency departments for managing severe acute pain, such as in cases of trauma^[1].
4. Sickle cell vaso-occlusive crisis: Research is being conducted on its use for pain management in children with sickle cell disease experiencing severe pain crises^[5].
5. Procedural sedation: Sufentanil is sometimes used in combination with other medications to provide conscious sedation for procedures like bronchoscopy^[6].

Administration Methods

Sufentanil can be administered through various routes, depending on the specific medical situation:

• Intravenous (IV): Directly into a vein, often used in hospital settings^[4].
• Sublingual: Under the tongue, using specially designed tablet systems like Zalviso or DSUVIA^[2][3].
• Intranasal: Sprayed into the nose, which is being studied for rapid pain relief in emergency situations^[1][5].
• Patient-Controlled Analgesia (PCA): Systems that allow patients to self-administer doses within prescribed limits^[2].

Effectiveness of Sufentanil

Sufentanil is known for its rapid onset of action and potent pain-relieving properties. Studies have shown its effectiveness in various scenarios:

• In post-operative pain management, it has been found to provide effective pain relief, potentially reducing the need for other opioids^[3].
• When used as part of anesthesia protocols, it can help maintain stable pain control during surgeries^[4].
• In emergency settings, intranasal sufentanil is being investigated for its potential to provide rapid pain relief, which could be particularly beneficial in situations where establishing IV access is challenging or time-consuming^[1].

Potential Side Effects

As with all opioid medications, sufentanil can cause side effects. Common side effects may include:

• Nausea and vomiting
• Dizziness
• Drowsiness or sedation
• Itching
• Constipation

More serious side effects that require immediate medical attention include:

• Respiratory depression: Slowed or shallow breathing, which can be dangerous^[6].
• Hypotension: Low blood pressure^[7].
• Bradycardia: Slow heart rate^[5].

Healthcare providers closely monitor patients receiving sufentanil to manage these potential side effects^[5].

Comparisons with Other Medications

Researchers are actively comparing sufentanil to other pain management medications to determine its relative benefits and risks:

• Sufentanil vs. Morphine: Studies suggest that sufentanil may provide faster pain relief and potentially fewer side effects compared to traditional morphine in some situations^[3].
• Sufentanil vs. Remifentanil: Both are potent, short-acting opioids used in anesthesia, with ongoing research comparing their effects on heart rate and blood pressure during surgery^[8].
• Sufentanil vs. Oliceridine: Oliceridine is a newer opioid medication being compared to sufentanil for post-operative pain management, with a focus on potentially reducing side effects^[7].

Ongoing Research

Several clinical trials are currently underway to further explore the uses and effects of sufentanil:

• Investigating its use in combination with other medications for procedural sedation, such as during bronchoscopies^[6].
• Studying the effectiveness of intranasal sufentanil for rapid pain relief in emergency situations, particularly in pediatric patients with sickle cell disease^[5].
• Comparing different administration methods (e.g., infusion vs. bolus dosing) to optimize pain control and reduce side effects in surgical settings^[4].
• Evaluating its potential to reduce hospital length of stay and improve overall pain management in orthopedic surgeries^[3].

These ongoing studies aim to refine the use of sufentanil, potentially expanding its applications while minimizing risks to patients.